Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 73.8% in June

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 260,360 shares, an increase of 73.8% from the May 31st total of 149,795 shares. Currently, 8.3% of the company’s stock are short sold. Based on an average daily volume of 693,061 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Valion Bio, Inc. Common Stock Stock Performance

VBIO stock traded down $0.03 on Thursday, hitting $0.49. The company had a trading volume of 29,721 shares, compared to its average volume of 272,099. The company has a current ratio of 3.31, a quick ratio of 3.02 and a debt-to-equity ratio of 0.62. Valion Bio, Inc. Common Stock has a 12-month low of $0.46 and a 12-month high of $5.60. The stock has a market cap of $1.57 million, a price-to-earnings ratio of -0.07 and a beta of 1.82. The stock’s 50-day simple moving average is $0.82 and its 200 day simple moving average is $1.03.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.

Valion Bio, Inc. Common Stock Company Profile

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.